Alkermes (ALKS) Asset Writedowns and Impairment (2012 - 2017)
Alkermes' (ALKS) quarterly Asset Writedowns and Impairment came in at $10.5 million in Q3 2017, up 213.81% quarter-over-quarter from $3.3 million in Q3 2013.
Powered by 
Analysis
Alkermes (ALKS) Asset Writedowns and Impairment (2012 - 2017) Analysis & Trends
Alkermes (ALKS) has reported Asset Writedowns and Impairment for 3 consecutive years, with $10.5 million the latest figure, recorded in Q3 2017.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $10.5 million in Q3 2017; TTM through Sep 2017 was $20.5 million, a N/A change from a year earlier, with the FY2021 full-year figure at $977000.0, changed N/A from the prior year.
- Asset Writedowns and Impairment was $10.5 million for Q3 2017 at Alkermes, up from $3.3 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $10.5 million in Q3 2017 and troughed at $3.3 million in Q1 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Alkermes | 7.58 Bn | 6.92 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | 10.50 Mn |
| Sep 30, 2013 | 3.35 Mn |
| Jun 30, 2013 | 3.35 Mn |
| Mar 31, 2013 | 3.35 Mn |
| Sep 30, 2012 | 4.60 Mn |